Overview

Preoperative Downstaging of Extraperitoneal T3 Rectal Cancer: XELOXRT Versus XELACRT. A Multicenter, Phase III Study

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

- INTERACT study: to evaluate the pathological response rate in cT3 rectal cancer - LEADER study: to evaluate the impact on local control of local excision

Phase:

Phase 3

Details

Lead Sponsor:

Catholic University of the Sacred Heart